You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

indolent B-cell lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2

Active, not recruiting
  • Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • External Beam Radiation Therapy
  • Orbital Radiation
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Lymphoma, B-Cell Trial in Guangzhou (Rituximab Biosimilar, Pegylated Interferon a-2b)

Recruiting
  • Lymphoma, B-Cell
  • Rituximab Biosimilar
  • Pegylated Interferon α-2b
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Apr 6, 2022

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,

Completed
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +8 more
  • PI3K inhibitor BKM120
  • +3 more
  • Atlanta, Georgia
  • +1 more
Jun 27, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical

Completed
  • Multiple Myeloma
  • +7 more
  • Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Nov 2, 2022

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)

Completed
Has Results
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 20, 2022

Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma Trial (FT596, Cyclophosphamide,

Withdrawn
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • (no location specified)
Jun 28, 2023

Leukemia Trial in New York (therapeutic autologous lymphocytes, cyclophosphamide)

Active, not recruiting
  • Leukemia
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Nov 18, 2021

Severe COVID-19 Infection in CLL or B-NHL Who Received

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
    • (no location specified)
    Apr 6, 2023

    DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

    Not yet recruiting
    • DLBCL - Diffuse Large B Cell Lymphoma
    • +6 more
    • Bridging radiation therapy
    • +2 more
    • (no location specified)
    Jan 4, 2023

    Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

    Not yet recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +11 more
    • Biopsy
    • +5 more
    • Duarte, California
      City of Hope Medical Center
    Jan 3, 2023

    Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Seattle (Laboratory Biomarker

    Active, not recruiting
    Has Results
    • Follicular Lymphoma
    • +2 more
    • Laboratory Biomarker Analysis
    • Pembrolizumab
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 6, 2022

    Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

    Completed
    • Grade 3a Follicular Lymphoma
    • +9 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 31, 2023

    Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

    Recruiting
    • Aggressive B-Cell Non-Hodgkin Lymphoma
    • +19 more
    • CD47 Antagonist ALX148
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 9, 2022

    Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in Spokane, Salamanca (Zilovertamab vedotin,

    Recruiting
    • Chronic Lymphocytic Leukemia
    • +3 more
    • Spokane, Washington
    • +1 more
    Aug 12, 2022

    Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia Trial in Australia,

    Recruiting
    • Follicular Lymphoma
    • +7 more
    • Louisville, Kentucky
    • +4 more
    Mar 11, 2022

    Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With

    Recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
    • +8 more
    • Biospecimen Collection
    • +3 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Mar 8, 2023

    CLL, SLL, Richter's Transformation Trial in United States (TG-1801, Ublituximab)

    Recruiting
    • CLL
    • +9 more
    • TG-1801
    • Ublituximab
    • Fayetteville, Arkansas
    • +4 more
    Jan 20, 2023

    MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,

    Active, not recruiting
    • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
    • +9 more
    • BTK inhibitor PCI-32765
    • +5 more
    • Columbus, Ohio
      Ohio State University Medical Center
    Jun 27, 2022

    Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Mantle-Cell Trial in Providence (Rituximab, Bendamustine, Vincristine

    Active, not recruiting
    • Lymphoma, Non-Hodgkin
    • +5 more
    • Providence, Rhode Island
      Rhode Island Hospital and The Miriam Hospital
    Jul 19, 2021

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

    Suspended
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +7 more
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    Jan 20, 2023

    Indolent B-Cell Non-Hodgkin Lymphoma Trial in Worldwide (BI1206)

    Recruiting
    • Indolent B-Cell Non-Hodgkin Lymphoma
    • BI1206
    • Atlanta, Georgia
    • +8 more
    Mar 1, 2022

    DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
    • +2 more
    • Biospecimen Collection
    • +5 more
    • (no location specified)
    Sep 5, 2023

    R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial (CNTY-101, IL-2,

    Recruiting
    • R/R CD19-Positive B-Cell Malignancies
    • +2 more
    • CNTY-101
    • +2 more
    • Detroit, Michigan
    • +1 more
    Dec 21, 2022